Skip to content
10-Q

Quarterly Report

Aktis Oncology, Inc. AKTS

0001193125-26-216749

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 48.63M sh
Shares Diluted Q1 2026 · Mar 31, 2025 805.82K sh
Shares Outstanding Q1 2026 · Mar 31, 2026 53.4M sh
Shares Outstanding Q1 2026 · Dec 31, 2025 915.26K sh
Capex Q1 2026 · Mar 31, 2026 $1.85M
Capex Q1 2026 · Mar 31, 2025 $1.89M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$24.24M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$17.48M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $371.63M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $37.78M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $58.25M
Stockholders Equity Q1 2026 · Mar 31, 2026 $506.11M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$146.15M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$101.56M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$87.8M
Current Liabilities Q1 2026 · Mar 31, 2026 $27.91M
Current Liabilities Q1 2026 · Dec 31, 2025 $31.24M
Total Liabilities Q1 2026 · Mar 31, 2026 $70.69M
Total Liabilities Q1 2026 · Dec 31, 2025 $77.63M
Current Assets Q1 2026 · Mar 31, 2026 $543.94M
Current Assets Q1 2026 · Dec 31, 2025 $230.31M
Total Assets Q1 2026 · Mar 31, 2026 $576.8M
Total Assets Q1 2026 · Dec 31, 2025 $264.89M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.38
Eps Diluted Q1 2026 · Mar 31, 2025 −$18.60
Eps Basic Q1 2026 · Mar 31, 2026 −$0.38
Eps Basic Q1 2026 · Mar 31, 2025 −$18.60
Sga Expense Q1 2026 · Mar 31, 2026 $5.9M
Sga Expense Q1 2026 · Mar 31, 2025 $3.73M
Rd Expense Q1 2026 · Mar 31, 2026 $20.04M
Rd Expense Q1 2026 · Mar 31, 2025 $15.86M
Net Income Q1 2026 · Mar 31, 2026 −$18.33M
Net Income Q1 2026 · Mar 31, 2025 −$14.99M
Operating Income Q1 2026 · Mar 31, 2026 −$22.71M
Operating Income Q1 2026 · Mar 31, 2025 −$18.14M
Revenue Q1 2026 · Mar 31, 2026 $3.23M
Revenue Q1 2026 · Mar 31, 2025 $1.45M